Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation.
about
Aberrant Wnt Signaling in LeukemiaWnt Signaling in Cancer Stem Cell BiologyMesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?Survival regulation of leukemia stem cellsOutlier Analysis and Top Scoring Pair for Integrated Data Analysis and Biomarker Discovery.Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia.Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target.Decreased SFRP2 expression is associated with intermediate and poor karyotypes in de novo acute myeloid leukemiaAn integrated approach of gene expression and DNA-methylation profiles of WNT signaling genes uncovers novel prognostic markers in acute myeloid leukemia.Study of SFRP1 and SFRP2 methylation status in patients with de novo Acute Myeloblastic Leukemia.Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies.Epigenetics in systemic lupus erythematosus: leading the way for specific therapeutic agentsA promoter DNA demethylation landscape of human hematopoietic differentiation.miR-590-5p, miR-219-5p, miR-15b and miR-628-5p are commonly regulated by IL-3, GM-CSF and G-CSF in acute myeloid leukemia.The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL).PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer.APC2 and CYP1B1 methylation changes in the bone marrow of acute myeloid leukemia patients during chemotherapy.Understanding of leukemic stem cells and their clinical implications.Wnt signaling in leukemias and myeloma: T-cell factors are in control.Hypermethylation of secreted frizzled-related proteins predicts poor prognosis in non-M3 acute myeloid leukemiaForced expression of Wnt antagonists sFRP1 and WIF1 sensitizes chronic myeloid leukemia cells to tyrosine kinase inhibitors.Low expression of secreted frizzled-related protein 4 in aggressive pituitary adenoma.Methylation of SFRP5 is related to multidrug resistance in leukemia cells.Hyper-activation of WNT/β-catenin signaling pathway mediates anti-tumor effects of histone deacetylase inhibitors in acute T lymphoblastic leukemia.Wnt/ß-catenin: a new therapeutic approach to acute myeloid leukemia.RASSF1A hypermethylation is associated with ASXL1 mutation and indicates an adverse outcome in non-M3 acute myeloid leukemia.Arsenic trioxide increases expression of secreted frizzled-related protein 1 gene and inhibits the WNT/β-catenin signaling pathway in Jurkat cells.Suppression of miR-708 inhibits the Wnt/β-catenin signaling pathway by activating DKK3 in adult B-all.DNA Methylation Events as Markers for Diagnosis and Management of Acute Myeloid Leukemia and Myelodysplastic Syndrome.Clinical significance of reduced SFRP1 expression in acute myeloid leukemia.Consecutive epigenetically-active agent combinations act in ID1-RUNX3-TET2 and HOXA pathways for Flt3ITD+ve AML.
P2860
Q26738411-C109F55E-7CEC-4ED8-8934-36D3ED911D6CQ26746101-C89F6B5D-4796-4407-A611-EA1F85CBC741Q26746104-5BAC2B89-246A-4221-980D-E7D3E8E1C790Q28271278-66BAC2E4-8EF8-45EC-A11C-05530D7D0C29Q30992589-A219C9D3-50EB-4056-B93A-76E256E494B1Q33772607-2F81ED2C-BE32-487E-9A7F-57F9C948FC3DQ33847891-BADAF674-045E-402A-BFFD-C214E89A062BQ34121336-1B5A74FB-BD5A-45BA-8E82-58FBA5831304Q35141163-4CA6BB7B-D781-4A28-AE71-F7C1C5D6FE38Q35204798-BA4D3D39-7454-464A-82EC-5FB73A3E1C18Q35553581-AD20DE38-97E2-40CE-A00A-2F3DE366D5B8Q35620090-261CBCDF-3DDA-49A1-9A73-1FF3DF99F3C5Q35633573-BDF07CB9-CBF8-4A98-BAFD-83D13A51EF8AQ35690892-23F3DE99-E294-48B2-BFFE-AD30E0D1313BQ35752062-271B7831-9E63-4023-8557-11851DC7798DQ35958274-02D4B235-5062-4A5B-8A73-937F14450A7CQ36471888-BEF27E82-CF6C-45FF-A562-3CD7D852F865Q37406464-9DAF751C-8ED2-427A-A87E-3753A86024E7Q37616010-DA62556B-075B-4C8F-8E18-2417C98305E8Q38155205-D73615FD-F874-4A0E-89D3-F46FE4BBA8AEQ38695398-B3740365-06B9-4349-B7A4-02A8F9CFE036Q38705028-D868B85F-F659-4079-BAC0-141DB9E2F64BQ38985965-4CFE1130-3FCA-41FB-83FF-8280AD073822Q39033727-DCD89D03-360B-4047-8672-F502D7D96A7CQ39401953-6A5393F6-ECD7-4E6C-A1DF-436EED7D270EQ39799555-47809665-302E-4539-9B16-7D2B3B0B4090Q41545370-3244CCAE-C39B-45B0-94F4-C467CFA91135Q41788771-EB482AD2-A85F-41F7-84FC-39FD15523AA4Q41940928-51786D89-26FB-40AF-B13E-323CF30EC074Q42361215-09990C57-23EF-4394-91D0-55B11A02BF6BQ44602971-0F6F0231-FC9F-4182-8353-85385E3A9E38Q49787877-5B0FBE67-4141-4C21-B7FD-4F94402F77C4
P2860
Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Acute myeloid leukemia is char ...... tor promoter hypermethylation.
@en
Acute myeloid leukemia is char ...... tor promoter hypermethylation.
@nl
type
label
Acute myeloid leukemia is char ...... tor promoter hypermethylation.
@en
Acute myeloid leukemia is char ...... tor promoter hypermethylation.
@nl
prefLabel
Acute myeloid leukemia is char ...... tor promoter hypermethylation.
@en
Acute myeloid leukemia is char ...... tor promoter hypermethylation.
@nl
P2093
P2860
P1433
P1476
Acute myeloid leukemia is char ...... tor promoter hypermethylation.
@en
P2093
B Douglas Smith
Craig Hooker
Elizabeth A Griffiths
Helai P Mohammad
Hetty E Carraway
James G Herman
Judith E Karp
Michael A McDevitt
Steven D Gore
P2860
P304
P356
10.3109/10428194.2010.496505
P577
2010-09-01T00:00:00Z